Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 466 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... April 6, 2022 County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19 March 17, 2020 FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe... November 20, 2019 Load more HOT NEWS A Summer Poem Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer England moves to a single-dose HPV vaccine Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST...
